CA2157758A1 - Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokine - Google Patents
Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokineInfo
- Publication number
- CA2157758A1 CA2157758A1 CA002157758A CA2157758A CA2157758A1 CA 2157758 A1 CA2157758 A1 CA 2157758A1 CA 002157758 A CA002157758 A CA 002157758A CA 2157758 A CA2157758 A CA 2157758A CA 2157758 A1 CA2157758 A1 CA 2157758A1
- Authority
- CA
- Canada
- Prior art keywords
- des
- que
- est
- une
- les
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FRFR93/03230 | 1993-03-19 | ||
FR9303230A FR2702659B1 (fr) | 1993-03-19 | 1993-03-19 | Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine. |
FRFR93/03787 | 1993-03-31 | ||
FR9303787A FR2703251B3 (fr) | 1993-03-31 | 1993-03-31 | Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine . |
PCT/FR1994/000307 WO1994021275A1 (fr) | 1993-03-19 | 1994-03-21 | Compositions pour l'application en therapeutique humaine, caracterisees par l'association d'un muramyl-peptide a une cytokine |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2157758A1 true CA2157758A1 (en) | 1994-09-29 |
Family
ID=26230187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002157758A Abandoned CA2157758A1 (en) | 1993-03-19 | 1994-03-21 | Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokine |
Country Status (11)
Country | Link |
---|---|
US (1) | US5932208A (ja) |
EP (1) | EP0689449B1 (ja) |
JP (1) | JP3723206B2 (ja) |
AT (1) | ATE226828T1 (ja) |
AU (1) | AU6285694A (ja) |
CA (1) | CA2157758A1 (ja) |
DE (1) | DE69431620T2 (ja) |
DK (1) | DK0689449T3 (ja) |
ES (1) | ES2187520T3 (ja) |
PT (1) | PT689449E (ja) |
WO (1) | WO1994021275A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4411592A1 (de) | 2023-02-06 | 2024-08-07 | Sick Ag | Verfahren zum lesen eines optischen codes und optoelektronischer codeleser |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159460A (en) * | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US6267968B1 (en) * | 1995-04-07 | 2001-07-31 | Vacsyn S.A. | MDP derivatives and conjugates having haematipoietic function stimulating activity, and compositions containing same |
JP4771563B2 (ja) | 1996-12-06 | 2011-09-14 | アムジエン・インコーポレーテツド | Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法 |
US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
US6013253A (en) * | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
MXPA02009454A (es) | 2000-03-31 | 2003-04-10 | Purdue Research Foundation | Metodo de tratamiento usando conjugados ligando-inmunogeno. |
FR2809106A1 (fr) * | 2000-05-17 | 2001-11-23 | Istac | Polypeptide ro/ssa-like et ses fragments et polynucleotides codant lesdits polypeptides et applications therapeutiques |
AU2002316384A1 (en) * | 2001-06-26 | 2003-03-03 | Photomed Technologies, Inc. | Multiple wavelength illuminator |
MXPA04000134A (es) | 2001-06-26 | 2005-06-06 | Abgenix Inc | Anticuerpos para ligandos de osteoprotegerina. |
KR20040053136A (ko) * | 2001-09-28 | 2004-06-23 | 펄듀 리서치 파운데이션 | 리간드-면역원 공액체를 이용한 치료 방법 |
US20030097409A1 (en) * | 2001-10-05 | 2003-05-22 | Hungchou Tsai | Systems and methods for securing computers |
BRPI0314038B8 (pt) | 2002-09-06 | 2021-05-25 | Amgen Inc | anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica |
WO2004060911A2 (en) * | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
US7546638B2 (en) * | 2003-03-18 | 2009-06-09 | Symantec Corporation | Automated identification and clean-up of malicious computer code |
DK1708690T3 (en) | 2003-11-17 | 2016-11-07 | Biomarin Pharm Inc | TREATMENT OF PHENYLKETONURI WITH BH4 |
US8003126B2 (en) * | 2004-11-17 | 2011-08-23 | Biomarin Pharmaceutical Inc. | Stable tablet formulation |
AR056806A1 (es) | 2005-11-14 | 2007-10-24 | Amgen Inc | Moleculas quimericas de anticuerpo rankl- pth/ pthrp |
US8168164B2 (en) * | 2006-02-03 | 2012-05-01 | Purdue Research Foundation | Targeted conjugates and radiation |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
US8323635B2 (en) | 2007-11-14 | 2012-12-04 | General Regeneratives, Ltd. | Methods of using interleukin-1 receptor antagonist as a myeloprotective agent |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
CN101690801B (zh) | 2009-10-26 | 2012-08-01 | 上海交通大学 | 白细胞介素-1受体拮抗剂的用途及其药物组合物 |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
US10041044B2 (en) | 2016-07-29 | 2018-08-07 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
EP3836954A1 (en) | 2018-08-13 | 2021-06-23 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK585886A (da) * | 1985-12-24 | 1987-06-25 | Takeda Chemical Industries Ltd | Immunstimulerende middel og anvendelse deraf |
IL83350A0 (en) * | 1986-08-13 | 1987-12-31 | Takeda Chemical Industries Ltd | Pharmaceutical compositions comprising interleukin and intterferon active substances |
GB8803365D0 (en) * | 1988-02-13 | 1988-03-16 | Ciba Geigy Ag | Antiviral combination |
-
1994
- 1994-03-21 CA CA002157758A patent/CA2157758A1/en not_active Abandoned
- 1994-03-21 DK DK94910445T patent/DK0689449T3/da active
- 1994-03-21 AT AT94910445T patent/ATE226828T1/de not_active IP Right Cessation
- 1994-03-21 EP EP94910445A patent/EP0689449B1/fr not_active Expired - Lifetime
- 1994-03-21 JP JP52072694A patent/JP3723206B2/ja not_active Expired - Fee Related
- 1994-03-21 ES ES94910445T patent/ES2187520T3/es not_active Expired - Lifetime
- 1994-03-21 AU AU62856/94A patent/AU6285694A/en not_active Abandoned
- 1994-03-21 PT PT94910445T patent/PT689449E/pt unknown
- 1994-03-21 DE DE69431620T patent/DE69431620T2/de not_active Expired - Fee Related
- 1994-03-21 WO PCT/FR1994/000307 patent/WO1994021275A1/fr active IP Right Grant
- 1994-03-21 US US08/522,342 patent/US5932208A/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4411592A1 (de) | 2023-02-06 | 2024-08-07 | Sick Ag | Verfahren zum lesen eines optischen codes und optoelektronischer codeleser |
Also Published As
Publication number | Publication date |
---|---|
WO1994021275A1 (fr) | 1994-09-29 |
DK0689449T3 (da) | 2003-03-03 |
PT689449E (pt) | 2003-03-31 |
ATE226828T1 (de) | 2002-11-15 |
JPH08511235A (ja) | 1996-11-26 |
ES2187520T3 (es) | 2003-06-16 |
EP0689449A1 (fr) | 1996-01-03 |
EP0689449B1 (fr) | 2002-10-30 |
DE69431620T2 (de) | 2003-07-03 |
US5932208A (en) | 1999-08-03 |
JP3723206B2 (ja) | 2005-12-07 |
AU6285694A (en) | 1994-10-11 |
DE69431620D1 (de) | 2002-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2157758A1 (en) | Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokine | |
Barth et al. | The role of adjuvant therapy in melanoma management | |
CA2111580C (fr) | Composes immunogenes a effet notamment anti-cytokine, procede de preparation, compositions pharmaceutiques et kits les renfermant | |
US20130164255A1 (en) | Immunotherapy for reversing immune suppression | |
EP2684569A1 (en) | A composition for treatment of advanced prostate cancer | |
FR2774697A1 (fr) | Procede de sensibilisation de cellules presentatrices d'antigene et moyens pour la mise en oeuvre du procede | |
CA2322712A1 (fr) | Methodes d'activation de cellules tueuses naturelles (nk) | |
Salem et al. | Paracrine release of IL-12 stimulates IFN-γ production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine | |
AU2002342151A1 (en) | Immunotherapy for reversing immune suppression | |
US20040120926A1 (en) | Reactive oxygen metabolite inhibitors for use in compositions and methods of treatment | |
Nijen Twilhaar et al. | Incorporation of toll-like receptor ligands and inflammasome stimuli in GM3 liposomes to induce dendritic cell maturation and T cell responses | |
Mullins et al. | Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation | |
Agarwala et al. | Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment | |
EP0579791B1 (fr) | Utilisation d'une composition cellulaire pour le traitement des organismes humains ou animaux | |
US20210353745A1 (en) | Methods and reagents to treat allergy | |
Prussick et al. | Recurrence of pemphigus vulgaris associated with interleukin 2 therapy | |
US20100197595A1 (en) | Treatment of melanoma with alpha thymosin peptides | |
Lotzová et al. | Function of Interleukin-2-Activated NK Cells in Leukemia Resistance and Treatment | |
WO2001080836A1 (fr) | Utilisation de vecteurs particulaires dans l'immunomodulation | |
FR2703251A1 (fr) | Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine . | |
FR2702659A1 (fr) | Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine. | |
Bear et al. | Biologic therapy of melanoma with cytokines and lymphocytes | |
McCulloch et al. | Lymphokine‐activated killer (LAK) cells modulate the effects of IL‐2 on a T cell‐mediated immune response | |
EP0819136B1 (fr) | Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et composition les contenant | |
WO2023176896A1 (ja) | 糸状菌感染症の治療薬及び糸状菌感染症の治療方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |